The Latest Breaking News from ENVB

Enveric Biosciences Reports Full-Year 2021 Financial Results

  Enveric Biosciences Inc. (NASDAQ:ENVB) reported its financial results for the full year ended December 31, 2021. 2021 Financial Results Comprehensive net loss for the year was $48.8 million, including $36.3 million in net non-cash expenses, with a basic and diluted loss per share of $2.07, as compared to a…

Benzinga · Apr 1, 2022

Psilocybin For Cancer Related Distress: Enveric To Launch Clinical Trial In Partnership With University of Calgary

Enveric Biosciences (NASDAQ: ENVB) a neuroscience company developing psychedelics and cannabinoids into mental health medicines, announced a collaboration with the University of Calgary’s Hotchkiss Brain Institute.

Benzinga · Feb 17, 2022

Enveric Biosciences Closes $10 Million Public Offering

Psychedelics-based company Enveric Biosciences (NASDAQ: ENVB) has closed its previously announced underwritten public offering of 20 million shares of its common stock and warrants to purchase up to 20 million shares of its common stock for gross proceeds of approximately $10 million, befor

Benzinga · Feb 16, 2022